More Product Faster: Maximize mAbs, Cell Therapy, and Gene Therapy Production with Upstream Process Intensification

This webcast features: Charles Hill, Senior Field Application Scientist, Upstream, Repligen.

Implementation of upstream process intensification for biologics, cell therapies, and gene therapies has become necessary to meet the increasing demand for these advanced therapeutics. Upstream intensification is a critical first step in delivering more product faster at a reduced cost and with a smaller footprint.

This webinar from one of Repligen's expert application scientists dives into the role of upstream process intensification in scaling up productivity without compromising quality. Through real-world case studies, we will explore how Repligen's cutting-edge XCell® ATF System and KrosFlo® TFDF® System are revolutionizing upstream applications like N-1 perfusion, N perfusion and high-cell density transfection/infection processes focused on mAbs, AAV, LV, T cells, and other modalities.

Alternating Tangential Flow Filtration (ATF) is used across the industry as a robust cell retention device for upstream process intensification. Tangential Flow Depth Filtration (TFDF) can be used in harvest and clarification and in upstream intensification for large biomolecules including virus particles. The cell densities achieved by these cell retention processes in clinical and commercial processes can reach greater than 100x106 cells/mL. The applications to be presented have yielded anywhere between 2 – 80 fold increases in mAbs, AAV, or LV as well as 4 – 10 fold increases in peak viable cell densities.

Key Takeaways:

Register or Login and hit Watch on Demand to view the recorded webcast now.